Oral fluoropyrimidines in cancer treatment.
Lewis
N L
NL
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Meropol
N J
NJ
D000284:Administration, Oral; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage*; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage*; D014498:Uracil / Q000008:administration & dosage* / Q000031:analogs & derivatives*
C417063:5-chlorodihydroxypyridine; D000964:Antimetabolites, Antineoplastic; D011725:Pyridines; D003841:Deoxycytidine; D005641:Tegafur; C073482:eniluracil; D014498:Uracil; D000069287:Capecitabine; D005472:Fluorouracil